Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery.
Breast, 2010
[Epub ahead of print] Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery.
Trastuzumab delivery and changes in left ventricular ejection fraction (LVEF) in 110 patients receiving adjuvant trastuzumab in routine practice are investigated.
11 (10%) completed treatment despite delay(s) to allow LVEF recovery, 7 (6%) discontinued trastuzumab because of insufficient LVEF recovery, 2 (2%) of whom developed symptomatic cardiotoxicity.
With the newer guidelines, the value of LVEF lower limit of normal is important in determining the proportion of patients who require angiotensin-converting enzyme inhibitors (ACEIs) and cardiology referral: up to 100% could potentially complete trastuzumab on schedule with up to 60% receiving ACEIs and 25% requiring cardiology referral.
The new guidelines potentially allow more patients to complete trastuzumab on schedule but require higher levels of cardiological intervention.
View rest of article at www.ncbi.nlm.nih.gov «
Related articles
Below are some of our articles related to the article above:
The TRIP Database is a clinical search tool designed to allow health professionals to rapidly identify the highest quality clinical evidence for clinical practice.
Registered users (registration is free) benefit from extra features such as CPD, search history, and collaborative tools. Register here, or Login if you have registered before.
Find out more about Trip Database.
